More ImpediMed Limited news
ImpediMed LimitedASX: IPD

SOZO obtains CE Mark for Heart Failure Patient Monitoring

Jun 20, 2017 at 10:47 PM EDT · Issued by ImpediMed Limited

Filed with ASX · Jun 20, 2017 at 10:47 PM EDT · 2 pages · English

On 6ix: 6ix.com/news/sozo-obtains-ce-mark-for-heart-failure-patient-monitoring

Watch ImpediMed's latest callImpediMed (ASX:IPD) Q1 2027 Earnings Call · Replay · Oct 29↗

ImpediMed Limited on 6ix

Earlier from ImpediMed

  • Macquarie University Commences Lymphoedema Study Using SozoJun 14, 2017
  • L-Dex Study - Significant Reduction in Clinical LymphoedemaMay 17, 2017
  • March 2017 Quarter Results & Investor Conference CallApr 25, 2017
  • SOZO Shipped to Vanderbilt to Commence At-Home StudyApr 23, 2017
  • Placement of First SOZO Unit at Scripps HealthMar 6, 2017

Later from ImpediMed

  • L-Dex Recommended in Clinical Practice GuidelinesJul 4, 2017
  • IPD Submits FDA 510(k) Application for SOZO for LymphoedemaJul 16, 2017
  • Appendix 4C - Quarter ended 30 June 2017Jul 23, 2017
  • First patient enrolled in SOZO CHF Trial at Scripps HealthAug 8, 2017
  • US FDA 510(k) Clearance Issued for SOZO with L-DexAug 14, 2017
All ImpediMed news releases↗

Follow ImpediMed into a list and get an email when it puts out news.

Follow ImpediMed
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer